Stroke:研究发现西欧国家近几十年来脑卒中死亡率下降而发病率增高

2012-12-20 Stroke 互联网 geniusgodyu

在西欧,过去几十年里缺血性卒中的死亡率显着下降。年龄性别特异性缺血性卒中的死亡、缺血性卒中发病率、发病后30天病死率和住院后1年死亡率是用来描述新千年里缺血性卒中死亡率改变趋势的重要指标。为了检验缺血性卒中的死亡率和发病率之间的匹配情况,荷兰乌德勒支医学中心Julius生命科学和初级救护中心的IloncaVaartjes博士等人进行了一项研究,研究结果在线发表在2012年12月4日的Stroke杂

在西欧,过去几十年里缺血性卒中的死亡率显着下降。年龄性别特异性缺血性卒中的死亡、缺血性卒中发病率、发病后30天病死率和住院后1年死亡率是用来描述新千年里缺血性卒中死亡率改变趋势的重要指标。为了检验缺血性卒中的死亡率和发病率之间的匹配情况,荷兰乌德勒支医学中心Julius生命科学和初级救护中心的IloncaVaartjes博士等人进行了一项研究,研究结果在线发表在2012年12月4日的Stroke杂志上。研究结果发现:近几十年来缺血性卒中的死亡率呈显着下降趋势,但缺血性卒中的发病率并没有改变,甚至有轻微的增加。缺血性卒中是残疾的首要原因。非致死性缺血性卒中的增加趋势为社会带来了巨大的人力和经济负担,应加强缺血性卒中的预防。

研究人员根据死亡年份、性别、年龄对荷兰1980-2010年所有缺血性卒中死亡病例进行分组。节点回归使用于检验某个时间点显着的改变趋势。链接到国家范围内注册,构建一组于1997-2005年因缺血性卒中首次入院的队列,计算年龄性别特异的发病后30天病死率及发病后1年死亡率。根据年龄和性别计算缺血性卒中发病率(包括住院缺血性卒中患者和院外缺血性卒中死亡患者)。使用Mann-Kendall检验进行趋势评价。

研究结果显示:缺血性卒中在1980-2000年死亡率持续下降,某些年龄性别组在1990年代出现了衰减。除年轻男性组外,所有年龄性别组在2000年以后的缺血性卒中死亡率均显着下降。在几乎所有的年龄性别组也可以看到发病后30天病死率和发病后1年死亡率的下降。然而,缺血性卒中的发病率在1997-2005年保持稳定,甚至轻微增加。

该研究发现:近几十年缺血性卒中的死亡率显着下降与非致死性缺血性卒中事件数量的下降并不匹配。这很令人担忧,因为缺血性卒中已经是成人残疾的首要病因,带来了沉重的人力和经济负担。由此可见,目前最重要的是加强缺血性卒中的预防。

脑卒中相关的拓展阅读:

doi: 10.1161/STROKEAHA.112.677724
PMC:
PMID:

Remarkable Decline in Ischemic Stroke Mortality Is not Matched by Changes in Incidence

Vaartjes I, O'Flaherty M, Capewell S, Kappelle J, Bots M.

BACKGROUND AND PURPOSE: In Western Europe, mortality from ischemic stroke (IS) has declined over several decades. Age-sex-specific IS mortality, IS incidence, 30-day case fatality, and 1-year mortality after hospital admission are essential for explaining recent trends in IS mortality in the new millennium. METHODS: Data for all IS deaths (1980-2010) in the Netherlands were grouped by year, sex, and age. A joinpoint regression was fitted to detect points in time at which significant changes in the trends occur. By linking nationwide registers, a cohort of patients first admitted for IS between 1997 and 2005 was constructed and age-sex-specific 30-day case fatality and 1-year mortality were computed. IS incidence (admitted IS patients and out-of-hospital IS deaths) was computed by age and sex. Mann-Kendall tests were used for trend evaluation. RESULTS: IS mortality declined continuously between1980 and 2000 with an attenuation of decline in the 1990s in some of the age-sex groups. A remarkable decline in IS mortality after 2000 was observed in all age-sex groups, except for young men. An improved decline in 30-day case fatality and in 1-year mortality was also observed in almost all age-sex groups. In contrast, IS incidence remained stable between 1997 and 2005 or even increased slightly. CONCLUSIONS: The recent remarkable decline in IS mortality was not matched by a decline in the number of incident nonfatal IS events. This is worrying, because IS is already a leading cause of adult disability, claiming a heavy human and economic burden. Prevention of IS is therefore now of the greatest importance.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747090, encodeId=3cd51e4709060, content=<a href='/topic/show?id=fe5e90513cb' target=_blank style='color:#2F92EE;'>#西欧国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90513, encryptionId=fe5e90513cb, topicName=西欧国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9635916609, createdName=bnjfx@138.com, createdTime=Mon Aug 05 06:50:00 CST 2013, time=2013-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823169, encodeId=5e36182316987, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Aug 07 14:50:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752983, encodeId=20681e5298311, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Apr 12 12:50:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561539, encodeId=fdd5156153907, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567548, encodeId=5d9a156e548aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747090, encodeId=3cd51e4709060, content=<a href='/topic/show?id=fe5e90513cb' target=_blank style='color:#2F92EE;'>#西欧国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90513, encryptionId=fe5e90513cb, topicName=西欧国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9635916609, createdName=bnjfx@138.com, createdTime=Mon Aug 05 06:50:00 CST 2013, time=2013-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823169, encodeId=5e36182316987, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Aug 07 14:50:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752983, encodeId=20681e5298311, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Apr 12 12:50:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561539, encodeId=fdd5156153907, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567548, encodeId=5d9a156e548aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747090, encodeId=3cd51e4709060, content=<a href='/topic/show?id=fe5e90513cb' target=_blank style='color:#2F92EE;'>#西欧国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90513, encryptionId=fe5e90513cb, topicName=西欧国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9635916609, createdName=bnjfx@138.com, createdTime=Mon Aug 05 06:50:00 CST 2013, time=2013-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823169, encodeId=5e36182316987, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Aug 07 14:50:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752983, encodeId=20681e5298311, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Apr 12 12:50:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561539, encodeId=fdd5156153907, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567548, encodeId=5d9a156e548aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747090, encodeId=3cd51e4709060, content=<a href='/topic/show?id=fe5e90513cb' target=_blank style='color:#2F92EE;'>#西欧国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90513, encryptionId=fe5e90513cb, topicName=西欧国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9635916609, createdName=bnjfx@138.com, createdTime=Mon Aug 05 06:50:00 CST 2013, time=2013-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823169, encodeId=5e36182316987, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Aug 07 14:50:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752983, encodeId=20681e5298311, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Apr 12 12:50:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561539, encodeId=fdd5156153907, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567548, encodeId=5d9a156e548aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2012-12-22 liuxiaona
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747090, encodeId=3cd51e4709060, content=<a href='/topic/show?id=fe5e90513cb' target=_blank style='color:#2F92EE;'>#西欧国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90513, encryptionId=fe5e90513cb, topicName=西欧国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e9635916609, createdName=bnjfx@138.com, createdTime=Mon Aug 05 06:50:00 CST 2013, time=2013-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823169, encodeId=5e36182316987, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Wed Aug 07 14:50:00 CST 2013, time=2013-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752983, encodeId=20681e5298311, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Apr 12 12:50:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561539, encodeId=fdd5156153907, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567548, encodeId=5d9a156e548aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Dec 22 05:50:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2012-12-22 liuxiaona

相关资讯

Stroke:停用他汀类药物影响颅内出血转归

       3月22日,《卒中》(Stroke)杂志在线发表的加拿大的一项研究显示:入院前他汀类药物的使用和颅内出血的转归没有关联;停用他汀类药物可能使转归恶化,或可能仅仅是预后较差的一个潜在标志。   研究人员根据加拿大卒中协作网的登记数据,对2003~2008年连续登记的2466例颅内出血病人(平均年龄为71岁;53.6%为男性)进行了分析。

[WSC 2012]神经保护剂的未来

       今年世界卒中大会[WSC]首次在巴西首都巴西利亚举行。包括中国在内的80多个国家的2000多名神经科医生参加了此次盛会。会议上,多位专家就神经保护等相关研究进行了深入探讨,并分享了即将启动的另一项大型研究——RECOVER研究的设计方案。        目前,脑蛋白水解物注射液在研究领域中仍然活跃并

Stroke:心理因素与卒中发生相关

       一项新研究发现,抑郁、紧张或对生活不满的老年人罹患卒中及死于卒中的风险升高。该研究显示,与心理社会痛苦水平最低的人相比,痛苦水平最高的人罹患卒中的风险显著升高,并且卒中死亡风险高达后者3倍。该研究于12月13日在线发表于《卒中》杂志。        该研究研究者美国明尼阿波利斯市明尼苏达大学医学副教

J NEUROL NEUROSUR PS:奖赏机制有利于卒中患者空间忽略症康复

       来自伦敦大学帝国理工学院和布鲁内尔大学的研究者们的一项研究显示,部分视野注视障碍的卒中患者在获得一定奖励后可能会表现更好。         约有1/3~1/2的卒中患者罹患空间忽略,这是一种视觉注意力障碍。是指患者不会注意到他们视野其中一侧的物体。在一些情况下,患者会只刮半边脸的胡子,或吃

Stroke:DWI-ASPECTS评分预测卒中溶栓预后

       最近一项发表于《Stroke》研究显示DWI-ASPECTS评分能够预测大脑中动脉梗塞患者rtPA溶栓后预后情况,DWI-ASPECTS评分低的患者,仍有可能因早期血管再通而获益,而DWI-ASPECTS评分≥7分的患者,其早期血管再通对预后无显著影响。 (DWI-ASPECTS评分不同的患者早期开通与否预后的比较) &

Diabetes:新型降糖药或可减少卒中后脑损伤

       在小鼠中开展的一项研究中,瑞典卡罗林斯卡医学院的科学家们发现了一种新的潜在疗法,可能减少2型糖尿病患者卒中后的脑损伤。所建议的药物已获批准用于2型糖尿病的治疗。然而,科学家们希望,这一新的研究成果,也可能开辟了减少其他卒中高风险患者卒中发作后脑损伤的可能性。该项研究已在线发表于Diabetes期刊[Diabetes 2012 Dec 3]。